APH vs HALO · P/E 40, rev $16.38B vs P/E 15, rev $857.7M
Amphenol Corporation (APH) versus Halozyme Therapeutics Inc (HALO) — a side-by-side from cached financials, not a winner call.
Amphenol Corporation (APH) is a electronic components company listed on US.
Halozyme Therapeutics Inc (HALO) is a biotechnology company listed on US.
Latest reported APH revenue for 2026-06-30 was $16.38B. Net income was $2.70B. APH currently screens at market cap $170.77B and trailing P/E 39.9.
Latest reported HALO revenue for 2026-06-30 was $857.7M. Net income was $380.0M. HALO currently screens at market cap $7.10B and trailing P/E 15.3.
APH currently screens at market cap $170.77B and trailing P/E 39.9. HALO currently screens at market cap $7.10B and trailing P/E 15.3.
Not investment advice. Open the APH and HALO stock pages for the full models.
Not investment advice.